Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics

Published: Thursday, November 07, 2013
Last Updated: Thursday, November 07, 2013
Bookmark and Share
Adds an additional proprietary ADC development program in oncology.

ADC Therapeutics Sarl and Five Prime Therapeutics, Inc. have announced an exclusive license agreement for human antibodies directed to an undisclosed target expressed on the surface of various types of cancers.

Under the agreement, ADC Therapeutics plans to initiate preclinical research and development of antibody-drug conjugates using the antibodies licensed from Five Prime immediately, adding to ADC Therapeutics’ portfolio of proprietary ADC programs.

ADC Therapeutics’ unique platform combines monoclonal antibodies specific to particular types of tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads.

As ADC Therapeutics’ PBD-based chemistries do not distort the structure of the DNA they give the prospect of highly potent, target-selective cancer therapies with fewer side effects and the potential to pre-empt resistance issues faced by other anti-cancer products on the market.

Dr. Peter B. Corr, Chairman of ADC Therapeutics and Managing General Partner of Auven Therapeutics, said: “We believe that ADCs offer a great opportunity to develop next generation oncology drugs that are more efficacious and with less side effects. The partnership with Five Prime further extends our exciting development portfolio of novel ADCs and we look forward to rapidly progressing the development plans.”

“ADC Therapeutics is a leader in developing proprietary antibody-drug conjugates targeting major cancers such as breast, lung, prostate, renal and blood,” said Lewis T. “Rusty” Williams, M.D., Ph.D., President and CEO of Five Prime.

Williams continued, “We believe that antibodies directed toward this protein target, which is found on a variety of tumor types, will be most efficacious when armed with a cytotoxic drug conjugate. This strategic license allows us to progress a program by leveraging Five Prime’s strength in the development of novel biologic products and ADCT’s complementary strength in arming antibodies for use in treating cancer.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ADC Therapeutics Expands Team
Company’s lead program, ADCT-301, to enter clinical development in early 2015.
Wednesday, October 08, 2014
ADC Therapeutics and BZL Biologics Announces Licensing and Collaboration Agreement
Company licenses proprietary antibody from BZL Biologics for prostate cancer.
Tuesday, July 16, 2013
Scientific News
How it Works: Advanced Data Analysis Using Visualization
Visualisation of data can be used to help molecular biologists tackle the vast datasets their experiments create.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Molecular Origins of Dust Mite Allergy Discovered
Scientists have identified molecules of house dust mites that are targeted by the immune system of children, developing allergic rhinitis and asthma.
Gene-Editing Cures Genetic Blood Disorder in Mice
New technology may offer minimally invasive treatment for genetic disorders of the blood.
Influential Cancer Researcher Receives Agilent Thought Leader Award
Biologist Scott Lowe receives award in recognition for his contributions to cancer biology.
New Compound Shows Promise in Treating Multiple Human Cancers
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of all cancers.
ALS Study Reveals Role of RNA-Binding Proteins
The findings are a significant step forward in validating RNA-based therapy as a treatment for ALS.
Observing Direct Inheritance of Gene-Silencing RNA
Research has allowed for the observation of double-stranded RNA molecule being passed from parent to offspring in roundworms.
Using CRISPR to Accelerate Search for HIV Cure
Gene-editing platform makes it easier to create HIV-resistant immune cells.
IU Research Reveals Link between Molecular Mechanisms in Prostate Cancer and Ewing's sarcoma
Researchers at IU have suggested that the molecular mechanism that triggers the rare disease Ewing's sarcoma could act as a potential new direction for the treatment of more than half of patients with prostate cancer.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos